ICON Public Limited (NASDAQ:ICLR) Receives Average Rating of “Moderate Buy” from Analysts

ICON Public Limited (NASDAQ:ICLR) has been given an average recommendation of “Moderate Buy” by the fifteen brokerages that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $283.92.

A number of brokerages have weighed in on ICLR. Truist Financial lowered their price target on ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Baird R W cut shares of ICON Public from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. JPMorgan Chase & Co. reduced their price target on shares of ICON Public from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. The Goldman Sachs Group dropped their price objective on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating for the company in a report on Friday, October 25th. Finally, Barclays decreased their price target on ICON Public from $330.00 to $275.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Icon Wealth Advisors LLC raised its stake in shares of ICON Public by 861.1% during the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after buying an additional 11,840 shares during the last quarter. Foyston Gordon & Payne Inc bought a new stake in shares of ICON Public during the 3rd quarter valued at $11,672,000. Tributary Capital Management LLC lifted its stake in shares of ICON Public by 116.1% in the 4th quarter. Tributary Capital Management LLC now owns 3,950 shares of the medical research company’s stock valued at $828,000 after purchasing an additional 2,122 shares during the period. GAMMA Investing LLC boosted its position in shares of ICON Public by 64.0% in the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after purchasing an additional 169 shares during the last quarter. Finally, Entropy Technologies LP boosted its position in shares of ICON Public by 472.2% in the 4th quarter. Entropy Technologies LP now owns 6,174 shares of the medical research company’s stock worth $1,295,000 after purchasing an additional 5,095 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

ICON Public Trading Up 5.5 %

Shares of ICLR stock opened at $201.84 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34. The firm has a fifty day moving average of $203.04 and a 200-day moving average of $246.13. ICON Public has a 52-week low of $181.51 and a 52-week high of $347.72. The stock has a market cap of $16.65 billion, a price-to-earnings ratio of 22.50, a P/E/G ratio of 1.73 and a beta of 1.19.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.01. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The firm had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.04 billion. On average, equities research analysts forecast that ICON Public will post 13.44 earnings per share for the current fiscal year.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.